Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 5/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 3/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 3/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.36 |
| ▸ | CDC25B | P30305 | 4/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774080 | 0.91 | SLC5A2 (0.37) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL1773968 | 0.91 | TACR2 (0.38) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL1775540 | 0.90 | SSTR4 (0.37) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12425880 | 0.86 | SLC5A2 (0.55) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12425951 | 0.86 | SLC5A2 (0.55) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12425828 | 0.86 | SLC5A2 (0.55) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12425934 | 0.86 | SLC5A2 (0.42) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12425937 | 0.85 | SLC5A2 (0.43) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL1774693 | 0.85 | SLC5A2 (0.38) | SLC5A2SSTR1SSTR2SSTR4SSTR3 | |
| SCHEMBL12425885 | 0.85 | SLC5A2 (0.57) | SLC5A2SSTR1SSTR2SSTR4SSTR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943748-B2 | Glucitol derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-05-17 | — | — | US | disclosed |
| US-20080319047-A1 | Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2008-12-25 | — | — | US | disclosed |
| EP-1803721-A1 | NOVEL GLUCITOL DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319047-A1 | Novel Glucitol Derivative, Prodrug Thereof And Salt Thereof, And Therapeutic Agent Containing The Same For Diabetes | SLC5A1, SLC5A2, GPR119 | SLC5A2 2/4885SSTR1 2006/4885SSTR2 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.